

ASX Announcement

Accomplished scientist Dr Sharon Yavrom appointed Executive Director, Clinical Scientist

Sydney, Australia, 01 July 2022: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, is pleased to announce the appointment of Dr Sharon Yavrom as Executive Director, Clinical Scientist, effective today.

Dr. Yavrom is an accomplished clinical scientist with nearly 20 years of industry experience in both established and emerging pharmaceutical companies. She has previously held positions at industry leading companies such as TAP Pharmaceuticals, Amgen and BMS and has spent her recent career lending her expertise to start-up companies such as Synta Pharmaceuticals, Puma Biotechnology, Tocagen, Aduro, MEI Pharma and Oncternal, with a focus on the oncology therapeutics space.

Dr. Yavrom has been the clinical study lead for several clinical trials and has experience with multiple tumour types including HER2+ breast cancer, NSCLC, glioblastoma, colorectal cancer, non-invasive bladder cancer, NHL, CLL and Ewing's Sarcoma.

Dr. Yavrom received her Bachelor of Science degree in Biology from San Jose State University and her Ph.D. in Pathobiology from University of Southern California, Keck School of Medicine.

Imugene's M.D. & CEO, Ms Leslie Chong said: "We are excited to welcome Sharon to the Imugene management team. She is a well-respected and highly skilled clinical scientist. Her experience with emerging pharmaceutical companies and oncology therapeutics makes her an ideal addition to our leadership team as we bring our clinical pipeline to fruition."

For more information please contact:

Leslie Chong
Managing Director and Chief Executive Officer
info@imugene.com

Investor Enquiries
investor@imugene.com



Media Enquiries

Matt Wright

matt@nwrcommunications.com.au

Follow us on Twitter @TeamImugene

Like us on Facebook @Imugene

Connect with us on LinkedIn @Imugene Limited

View us on YouTube @Imugene Limited

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Release authorised by the Managing Director and Chief Executive Officer

Imugene Limited, Level 3, 62 Lygon Street, Carlton, VIC, 3053, Australia